Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2025
Received overwhelming shareholder support in favour of take-private transaction with AditxtAdvanced key pipeline programs, engaged regulatory ...
Vistagen: Pherine Candidate Proof Of Concept Continues With Fifth Indication
Vistagen Therapeutics, Inc.'s fasedienol shows promise in treating social anxiety; new results expected 2025. Click for my ...
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Q4 2024 Earnings Call Transcript
Q4 2024 Earnings Call Transcript February 13, 2025 Vanda Pharmaceuticals Inc. beats earnings expectations. Reported EPS is ...
FDA approves first rapid-acting insulin
According to the FDA, the medication quickly helps to lower mealtime blood sugar spikes to improve control of blood sugar in ...
Healio23h
FDA approves subcutaneous Merilog for glycemic control in diabetes
The FDA has approved the first rapid-acting biosimilar insulin product for glycemic control in people with diabetes. Merilog ...
MedPage Today23h
FDA OKs First Rapid-Acting Insulin Biosimilar for Diabetes
The FDA approved insulin-aspart-szjj (Merilog) as the first rapid-acting insulin biosimilar product to treat adults and ...
Business Wire22h
U.S. FDA Grants Full Approval of Deciphera’s ROMVIMZA™ (vimseltinib) for the Treatment of Symptomatic Tenosynovial Giant Cell Tumor (TGCT)
Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Toichi Takino; “Ono”) announced that the U.S. Food and Drug Administration (FDA) ...